Bristol-Myers Squibb Company (BMY) stock moves up, “Buy” rating reaffirmed by Jefferies Group LLC Analysts

Bristol-Myers Squibb Company (NYSE: BMY) shares rose on Tuesday January 31 on lower trade volume than normal after a number of analysts weighed in on the investing value of the stock and reiterated thier respective ratings.

Meanwhile, The Dow Jones Industrial Average DJIA, -0.60% fell 140 points, or 0.7%, to 19,833, with 26 of the 30 blue-chip companies trading lower. Nike, Inc. NKE, -1.10% down 2.4% and Intel Corp. INTC, -1.70% off 1%, were leading losses.

The S&P 500 SPX, -0.33% was off by 10 points, or 0.5%, to 2,270 with seven of the 11 main sectors trading lower. Industrials, consumer-discretionary, and technology shares were the worst performers, while real estate and utilities stocks attracted buyers.

The health-care sector, which was down in early trade, rebounded after President Trump called for scaling back drugmaker’s regulation, lowering taxes and prices of medicines.

The Nasdaq Composite COMP, -0.25% declined 31 points, or 0.6%, to 5,581.

Bristol-Myers Squibb Company (NYSE: BMY) had its Buy rating reiterated by equities researchers at Jefferies Group LLC in a research note to investors. With a rating of Buy on the stock, Bristol-Myers Squibb Company has a 52-week high of $77.12. The one-year price target of $55.92 is above the opening price of $48.34, resulting a fair amount of other analysts to comment on the company recently. Usually, after analysts give a “reiterated rating” report on a stock, they will later issue periodic updates, often followed by a price target change.

Shares of Bristol-Myers Squibb Company (NYSE: BMY) opened at $48.34 yesterday trading between $48.21 and $48.85, and last traded at $48.78, which is an increase of $0.09 compared to the previous closing price.

Bristol-Myers Squibb Company (NYSE: BMY) currently has a market cap of 81.52B.

Bristol-Myers Squibb Company (NYSE: BMY) Average Daily Trading Volume

1,816,621 shares traded hands yesterday, 34 percent below normal, out of a total float 1,668,823,000. lower than normal. Look for trading volume to pick up in the coming days as momentum traders often use swings in trading volume to identify heavy volume accumulation or distribution by institutional investors.

However, a single day of heavy buy side trading is not enough to assert a trend. As such, market traders will continue to watch for institutional sponsorship as a signal that financial institutions are moving forward.

Institutional sponsorship simply refers to ownership of a stock by mutual funds, banks, pension funds and other large institutions.

These instituitional investors retain substantial teams of analysts researching thousands of stocks. So watching their interests is a good way to ensure you are buying the right stocks.

Bristol-Myers Squibb Company (NYSE: BMY) Moving Averages

A moving average can also act as support or resistance. In an uptrend a 50-day, 100-day or 200-day moving average may act as a support level, as shown in the figure below.

This is because the average acts like a floor (support), so the price bounces up off of it.

In a downtrend a moving average may act as resistance; like a ceiling, the price hits it and then starts to drop again.

By spotting trends, moving averages allow investors to make those trends work in their favor and increase the number of successful trades.

With that in mind, Bristol-Myers Squibb Company (NYSE: BMY) now has a 50-day MA of $56.28 and 200-day MA of $57.78. It has traded in a 52-week range between $46.01 – 77.12 and today’s last price is 36.75%% lower than the 52 week high of $77.12.

Earnings growth is a critical factor to research when buying stocks and investors identify companies that have been successful at growing their earnings by at least 25% over the past 3 years.

DISCLOSURE: The views and opinions expressed in this article do not represent the views of the website. Readers should not consider statements made by the author as formal recommendations and should consult their financial adviser before making any investment decisions. To read our full disclosure, please see our terms and conditions page.

Leave a Reply

Your email address will not be published. Required fields are marked *